Geode Capital Management LLC Cuts Stock Holdings in Option Care Health, Inc. $OPCH

Geode Capital Management LLC reduced its position in shares of Option Care Health, Inc. (NASDAQ:OPCH) by 2.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,117,393 shares of the company’s stock after selling 83,900 shares during the period. Geode Capital Management LLC’s holdings in Option Care Health were worth $131,200,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. Cornerstone Investment Partners LLC raised its holdings in Option Care Health by 3.4% during the fourth quarter. Cornerstone Investment Partners LLC now owns 9,773 shares of the company’s stock worth $311,000 after purchasing an additional 318 shares in the last quarter. Sheets Smith Wealth Management raised its holdings in Option Care Health by 1.3% during the fourth quarter. Sheets Smith Wealth Management now owns 26,167 shares of the company’s stock worth $834,000 after purchasing an additional 326 shares in the last quarter. Fifth Third Bancorp raised its holdings in Option Care Health by 21.9% during the fourth quarter. Fifth Third Bancorp now owns 2,328 shares of the company’s stock worth $74,000 after purchasing an additional 419 shares in the last quarter. ProShare Advisors LLC raised its holdings in Option Care Health by 1.3% during the fourth quarter. ProShare Advisors LLC now owns 35,533 shares of the company’s stock worth $1,132,000 after purchasing an additional 444 shares in the last quarter. Finally, Arizona State Retirement System raised its holdings in Option Care Health by 1.1% during the third quarter. Arizona State Retirement System now owns 48,472 shares of the company’s stock worth $1,346,000 after purchasing an additional 540 shares in the last quarter. 98.05% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Option Care Health

In other Option Care Health news, Director Timothy P. Sullivan acquired 24,154 shares of the company’s stock in a transaction dated Thursday, May 7th. The stock was acquired at an average cost of $20.69 per share, with a total value of $499,746.26. Following the purchase, the director directly owned 73,383 shares in the company, valued at approximately $1,518,294.27. This trade represents a 49.06% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director Harry M. Jansen Kraemer, Jr. acquired 36,610 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The shares were bought at an average price of $21.41 per share, with a total value of $783,820.10. Following the completion of the transaction, the director directly owned 450,000 shares in the company, valued at approximately $9,634,500. The trade was a 8.86% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders purchased 73,264 shares of company stock valued at $1,548,316. Corporate insiders own 1.70% of the company’s stock.

Option Care Health Trading Down 2.2%

Shares of Option Care Health stock opened at $20.07 on Friday. Option Care Health, Inc. has a 12-month low of $18.01 and a 12-month high of $36.80. The company has a current ratio of 1.64, a quick ratio of 1.07 and a debt-to-equity ratio of 0.85. The stock has a market cap of $3.15 billion, a PE ratio of 15.56, a price-to-earnings-growth ratio of 1.14 and a beta of 0.67. The company has a 50-day moving average of $24.48 and a two-hundred day moving average of $29.60.

Option Care Health (NASDAQ:OPCH) last issued its earnings results on Thursday, April 30th. The company reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.03. Option Care Health had a net margin of 3.64% and a return on equity of 18.17%. The company had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.39 billion. During the same period last year, the company posted $0.40 earnings per share. The firm’s quarterly revenue was up 1.3% compared to the same quarter last year. Option Care Health has set its FY 2026 guidance at 1.820-1.920 EPS. On average, research analysts anticipate that Option Care Health, Inc. will post 1.64 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms recently issued reports on OPCH. Bank of America cut shares of Option Care Health from a “buy” rating to a “neutral” rating and set a $22.00 price target for the company. in a report on Friday, May 1st. Truist Financial set a $30.00 price target on shares of Option Care Health in a report on Friday, May 1st. Stephens set a $30.00 target price on shares of Option Care Health in a report on Friday, May 1st. Zacks Research cut shares of Option Care Health from a “hold” rating to a “strong sell” rating in a report on Monday, May 11th. Finally, Wall Street Zen cut shares of Option Care Health from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $31.25.

Option Care Health Company Profile

Option Care Health (NASDAQ: OPCH) is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.

Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry’s most experienced home infusion businesses.